Benefits and risks of PD-1/PD-L1 inhibitors for recurrent small cell lung cancer: A systematic review and meta-analysis
Author:
Funder
Wu Jieping Medical Foundation
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference40 articles.
1. Pembrolizumab plus amrubicin in patients with relapsed SCLC: multi-institutional, single-arm phase 2 study;Akamatsu;JTO Clin. Res Rep.,2021
2. Immune checkpoint inhibitors in small cell lung cancer: a partially realized potential;Armstrong;Adv. Ther.,2019
3. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial;Baize;Lancet Oncol.,2020
4. SCLC treatment in the immuno-oncology era: current evidence and unmet needs;Belluomini;Front Oncol.,2022
5. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth;Chen;J. Immunother. Cancer,2020
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Applications of CT-based radiomics for the prediction of immune checkpoint markers and immunotherapeutic outcomes in non-small cell lung cancer;Frontiers in Immunology;2024-08-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3